Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T12:45:41.861Z.
Calculation as of: 2026-10-06T12:45:41.861Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
BlossomHill Therapeutics, Inc.
Market Cap
$579.88M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
Operating Cash Flow Yield
N/A
TTM Avg
8.85%
3Y Avg
8.85%
5Y Avg
8.85%
Market Cap
$569.56M
Operating Cash Flow Yield
44.58%
TTM Avg
19.98%
3Y Avg
17.70%
5Y Avg
17.70%
Market Cap
$596.36M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$561.67M
Operating Cash Flow Yield
N/A
TTM Avg
4.06%
3Y Avg
4.43%
5Y Avg
13.92%
Market Cap
$551.09M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$547.86M
Operating Cash Flow Yield
3.58%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
Market Cap
$632.76M
Operating Cash Flow Yield
N/A
TTM Avg
0.02%
3Y Avg
0.02%
5Y Avg
0.02%
Market Cap
$637.59M
Operating Cash Flow Yield
N/A
TTM Avg
1.57%
3Y Avg
5.72%
5Y Avg
13.10%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $579.88M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 8.85% | 8.85% | 8.85% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 44.58% | 19.98% | 17.70% | 17.70% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | N/A | 4.06% | 4.43% | 13.92% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 3.58% | 3.98% | 3.57% | 3.57% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | N/A | 0.02% | 0.02% | 0.02% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | N/A | 1.57% | 5.72% | 13.10% |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 536.71% | 536.71% | 536.71% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
